Somebody has to be watching for the vascular occlusion signs — and the uncomfortable structural fact of aesthetic practice is that at the moment most occlusions declare themselves, the only people looking are the patient and whoever answers your phone.
A referral clinic in the Netherlands catalogued 44 vascular adverse events over 25 months and calculated an incidence of roughly one in 6,600 treatments. The detail that should reorganise your aftercare is the timing: the fastest detection was three to five hours after injection, but most commonly the event was detected one day post-injection, with two cases identified as late as eight months and one referred only after an eight-week delay (Schelke L, Decates T, Kadouch J, Velthuis P. Incidence of Vascular Obstruction After Filler Injections. Aesthet Surg J. 2020;40(8):NP457-NP460. PMID 32538425).
Blindness is the exception — it presents during or within minutes of injection, while you are still in the room. Everything else usually does not. The typical cutaneous occlusion becomes recognisable after the patient has driven home, eaten dinner and gone to bed.
Melissa Pulcini-Buttine, PA, puts the consequence bluntly: "We could recognise it. But if your patient leaves and they don't know the signs to look for, then we're going to run into issues." Her framing for the whole subject is the one to build the systems on. "Recognition is a safety skill."
It is also a delegated skill, whether or not you have delegated it deliberately.
The instruction most clinics give does not work
The standard aftercare sheet says some swelling, redness and bruising are normal, and to call if anything seems wrong. That instruction fails in two specific ways.
First, it describes a vascular event as a subset of normal. Swelling, redness and bruising are exactly what early ischaemia looks like to someone with no clinical training. A patient told to expect redness will interpret dusky mottling as redness.
Second, it relies on pain. Most clinics' unwritten assumption is that a serious problem will hurt enough to prompt a call. The data do not support that. In a multinational survey of experienced injectors reporting intravascular events, the initial signs were minor livedo in 63%, pallor in 41% and pain in 37% — and pain was mild or absent in 47% of events (Goodman GJ, Roberts S, Callan P. Aesthetic Plast Surg. 2016;40(4):549-555. PMID 27286849).
Nearly half of vascular events do not hurt enough to trigger the call your aftercare sheet is relying on. "Call if it's painful" is not a safety net; it is a filter that removes half the cases.
What the patient actually needs to be told
The consensus position is unambiguous about the obligation: "All patients should be educated on the warning signs of a vascular occlusion and be provided with emergency contact details" (Murray G, Convery C, Walker L, Davies E. Guideline for the Management of Hyaluronic Acid Filler-induced Vascular Occlusion. J Clin Aesthet Dermatol. 2021;14(5):E61-E69. PMID 34188752).
Translating that into instructions a non-clinician can act on means describing appearances rather than naming signs. Five things belong on the sheet.
1. Pain that is out of proportion, or in the wrong place. The distinguishing feature is not severity but location and trajectory. The consensus phrases it as: "Sudden escalating pain during treatment either at the site of the injection or in a distant site is not normal." For the patient, the useful version is: pain that gets worse instead of better after the first few hours, or pain somewhere you were not injected. Melissa teaches the same marker — "unusual pain in an area that you didn't inject."
2. A change in skin colour, described in sequence. The classic progression is well characterised: "skin blanching, livedo reticularis, slow capillary refill, and dusky blue-red discoloration, followed a few days later by blister formation and finally tissue slough" (DeLorenzi C. Complications of injectable fillers, part 2: vascular complications. Aesthet Surg J. 2014;34(4):584-600. PMID 24692598). The consensus describes a five-stage progression from pallor through reticulation and a grey hue to pustules at around day three and then tissue breakdown.
Patients do not know the word livedo. They do understand "a pale patch," "a blotchy net-like or lacy purple pattern," "a grey or dusky area" and "spots like small pimples appearing around day three." Write it that way.
3. Skin that feels cool or numb compared with the same area on the other side. Give them the comparison instruction explicitly — most people cannot judge skin temperature without a reference point.
4. Any visual change at all. Blurring, a dark or missing patch in the field, double vision, a drooping lid, pain behind or around the eye. This category gets its own line and its own instruction, which is not "call us." Among reported filler blindness cases, presenting features included complete vision loss in 54.2%, pain in 56.3%, ophthalmoplegia in 54.2% and ptosis in 52.1% (Beleznay K, Carruthers JDA, Humphrey S, Carruthers A, Jones D. Aesthet Surg J. 2019;39(6):662-674. PMID 30805636).
5. Any neurological symptom — weakness on one side, difficulty speaking, confusion, a facial droop that is not where you injected. This is not theoretical. The same series reported central nervous system complications in 18.8% of cases, and a dedicated review of cerebral embolism after facial filler found 43 published cases including five deaths (Wang HC, Yu N, Wang X, et al. Aesthet Surg J. 2022;42(3):NP162-NP175. PMID 33856432).
Alongside the list, three practical elements make it work: a number that is actually answered out of hours, an explicit statement that calling is welcome and no question is too small, and a named timeframe — today, tomorrow morning, and again around day three. The day-three prompt matters because the pustular stage is a relatively consistent finding at that point and patients often assume by then that they are past the risk window.
One item belongs in the consent conversation rather than the aftercare sheet. Consensus guidance recommends that the patient consent in advance to having product dissolved if a vascular event is suspected (Goodman GJ, Magnusson MR, Callan P, et al. Aesthet Surg J. 2020;40(9):1009-1021. PMID 31693068). An injector who has to negotiate permission to dissolve during an emergency has lost time that the evidence says matters. Structuring consent documents to carry this properly is covered in what to include in Botox consent forms, and the same principles apply to filler consent.
The front desk is the actual detection system
Here is the part almost no practice has built, and it is the part that decides whether the aftercare sheet above ever reaches a clinician.
These patients frequently present to people who did not inject them — a point established in the emergency-medicine literature, which describes filler-induced vascular occlusion as a rising presentation to emergency departments (Soares DJ, Hynes SD, Yi CH, Shah-Desai S, Irving SC. Cosmetic Filler-Induced Vascular Occlusion: A Rising Threat Presenting to Emergency Departments. Ann Emerg Med. 2024;83(1):59-67. PMID 37565956). Inside your own practice, the first person to hear about an event is almost always the one who answers the phone.
Three principles follow directly from the clinical facts above.
Principle one: the front desk does not triage. It routes.
The single most dangerous thing a non-clinical staff member can do is make a clinical judgement, and the most common form that takes is reassurance. "That's normal after filler." "Swelling like that is expected." "Give it a couple of days and call back."
Your script should make that impossible. Not discouraged — impossible. The instruction is that no member of non-clinical staff tells a post-injection patient that anything is normal, ever, under any circumstances, regardless of how obviously routine it sounds. That is a clinical assessment, and the consensus is explicit that a suspected occlusion requires "an urgent face-to-face assessment," not phone management.
Principle two: a fixed list of trigger words, and one action
Give the front desk the patient-facing vocabulary, not the clinical vocabulary. If a caller who has had injectable treatment in the last seven days uses any of these — pain getting worse, pain somewhere I wasn't injected, pale patch, blotchy, purple, lacy, mottled, grey, dusky, cold, numb, spots appearing, blisters — the call is escalated to a clinician immediately. Not a message. Not a callback slot. Interrupt.
And a separate, higher tier: any mention of vision, the eye, weakness, speech or confusion. For those, the staff member does not wait for a clinician to become free. They tell the patient to go to the nearest emergency department or eye service now, they confirm the patient has someone to take them, and then they interrupt the clinician — who may be mid-treatment, and should be interrupted anyway.
Principle three: capture four facts while the patient is on the phone
These take ninety seconds and materially change what happens next.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Aesthetic & Injectable Training courses — live patients, expert faculty, and ongoing mentorship.
- When was the treatment? Date and, if possible, time.
- When did this start? Onset time is the variable every subsequent decision runs on, and patients reconstruct it badly if asked later.
- What does it look like right now? In the patient's own words, written down verbatim rather than paraphrased into clinical language.
- Any change in vision? Asked directly, every time, even if the patient has not mentioned it. Patients do not volunteer visual symptoms because they do not connect them to a cheek injection.
Recording these is not administrative tidiness. Time from onset to treatment is the variable that the management literature consistently treats as decisive: a high-dose pulsed hyaluronidase protocol reports no partial or complete skin loss "if the protocol was implemented within 2 days of the ischemic event onset" (DeLorenzi C. Aesthet Surg J. 2017;37(7):814-825. PMID 28333326).
Why this is a practice-development problem, not only a clinical one
Three reasons.
The event will be detected by your systems or not at all. Your anatomical skill determines how often an occlusion happens. Your aftercare and phone systems determine how quickly the ones that happen get treated. Those are separate competencies, and most practices have invested heavily in the first and not at all in the second.
The gap between a warned patient and an unwarned one is measured in days. A patient who was told what to look for calls at hour twelve. A patient who was told to expect swelling calls on day five, when the skin has broken down. The referral series above included a case that reached specialist care only after eight weeks. Nothing about the injection differed; what differed was whether anyone had told the patient what they were looking at.
Under-reporting means you cannot benchmark yourself against the field. The true incidence of vascular complications "is unknown because of underreporting by clinicians," and that means your own audit data is the only reliable signal you will ever have about your own practice. A clinic where events are recognised early and documented properly knows something about itself. A clinic where they are missed learns nothing and assumes it is doing well.
What the clinic needs decided before the day it happens
Melissa's instruction is to "have your protocols ready," and readiness has a specific, checkable content.
Hyaluronidase on site, in adequate quantity. Consensus guidance states that every clinic should hold reconstitutable hyaluronidase with a minimum of 7,500 units on site. The concept of a standing "filler crash cart" — the drugs, the documentation and the decisions assembled in advance — dates to the 2014 complications literature and remains the right model. What dissolution achieves and where its limits lie is covered in filler dissolve.
A named receiving service. Not "an eye hospital" — a specific ophthalmology service or emergency department, with a phone number, a travel time and a route, written down and posted where the front desk can see it.
A decision about the schedule. When an event happens, the treating clinician is unavailable for hours. Who cancels the afternoon, who tells the waiting patients, and who is authorised to make that call without asking? Practices that have not decided this in advance lose time negotiating it during the emergency.
A follow-up rule. The consensus is that "vascular occlusions that are treated promptly to clinical resolution still require follow up the next day." Build it into the booking system so it cannot be forgotten by a relieved clinician.
An annual rehearsal with the whole team present, including reception. The people who will detect the event are the people least likely to have been in the room when the protocol was written.
What changes on Monday
Rewrite the aftercare sheet so it describes appearances rather than naming signs, and so it does not lead with reassurance about swelling and bruising.
Write a one-page front desk script with the trigger words, the two escalation tiers and the four questions, and put it where the phone is.
Establish the rule that non-clinical staff never tell a post-injection patient that something is normal.
Name your receiving service and post the number.
And accept the division of labour that the timing data force on you. You control whether the event happens. Your patient and your receptionist largely control whether it is caught in time — and right now, in most practices, neither of them has been told what they are looking for.
"Train your patients, train your staff," as Melissa puts it. "Educate and talk to them about potential complications."
The teaching framing in this article reflects Melissa Pulcini-Buttine's clinical practice as taught in Empire Medical Training's hands-on curriculum. Technique is learned under supervision; this article is educational and is not a substitute for training.
Recognition is downstream of anatomy — the clinician still has to know what the skin findings mean and which territory is involved. Empire teaches that foundation in anatomical based aesthetics training and special anatomical cadaver aesthetics training, with regional injectable technique in complete dermal filler training. Region-specific reaction patterns are covered in common lip filler reactions and how to avoid them.
Melissa Pulcini-Buttine, PA — physician assistant of two decades; professor of anatomy and physiology for ~14 years; faculty member, Empire Medical Training; founder of an aesthetics practice in Greenwich, Connecticut.
Frequently Asked Questions
When do filler vascular occlusions usually present?
Blindness presents during or within minutes of injection. Cutaneous occlusion is different: in a referral series of 44 cases, the fastest detection was three to five hours after injection but the most common timing was one day post-injection, with outliers detected weeks and even months later. Most events therefore declare themselves after the patient has gone home.
Do all vascular occlusions hurt?
No, and relying on pain misses roughly half of them. In a survey of experienced injectors reporting intravascular events, pain was mild or absent in 47% of cases, while the most common initial signs were minor livedo in 63% and pallor in 41%. Aftercare instructions built around "call if it hurts" are unreliable.
What should post-filler discharge instructions include?
Five items described in plain language: pain that worsens or occurs outside the injected area; skin colour change through pale, blotchy or lacy purple, grey or dusky; skin that feels cool or numb compared with the other side; any visual change; and any neurological symptom. Add a number answered out of hours and prompts for day one and day three.
What should front desk staff do when a patient calls with a concern?
Route, never triage. Non-clinical staff should never tell a post-injection patient that a symptom is normal. Any trigger word — worsening pain, pale, blotchy, purple, mottled, grey, cold, numb, spots — means interrupting a clinician immediately. Any mention of vision, weakness, speech or confusion means directing the patient to emergency care straight away.
How much hyaluronidase should a clinic keep on site?
Consensus guidance recommends every clinic hold reconstitutable hyaluronidase with a minimum of 7,500 units available on site, as part of a standing emergency setup prepared before it is needed. Alongside it, a clinic should have a named receiving ophthalmology service or emergency department, with the phone number and route posted where staff can find it.
Disclaimer
This article reflects the clinical opinions and experience of Melissa Pulcini-Buttine, PA, an independent faculty member contributing to Empire Medical Training's curriculum. The views expressed are the author's own and do not necessarily represent those of Empire Medical Training.
It is professional education, not medical advice, and is no substitute for hands-on training or independent clinical judgment. Licensed clinicians remain responsible for their own patient selection, technique and outcomes, for verifying current product labelling, and for practising within their scope and applicable law. Empire Medical Training accepts no liability for reliance on this content.
